Online inquiry

IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14031MR)

This product GTTS-WQ14031MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14031MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3672MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ8881MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ14672MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ14414MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ5546MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ2104MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ3900MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ992MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-368
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW